Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer
Jae‐Young Kim, Eric A. Welsh, Bin Fang, et al.
Molecular Cancer Research (2016) Vol. 14, Iss. 10, pp. 1019-1029
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow, Trever G. Bivona
Nature reviews. Cancer (2017) Vol. 17, Iss. 11, pp. 637-658
Closed Access | Times Cited: 796
The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics
Danica Wiredja, Mehmet Koyutürk, Mark R. Chance
Bioinformatics (2017) Vol. 33, Iss. 21, pp. 3489-3491
Open Access | Times Cited: 238
Long non-coding RNAs in anti-cancer drug resistance
Qin-nan Chen, Chenchen Wei, Zhaoxia Wang, et al.
Oncotarget (2016) Vol. 8, Iss. 1, pp. 1925-1936
Open Access | Times Cited: 199
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
Wenjuan Liu, Yue Du, Ru Wen, et al.
Pharmacology & Therapeutics (2019) Vol. 206, pp. 107438-107438
Closed Access | Times Cited: 171
RAS: Striking at the Core of the Oncogenic Circuitry
Ryan C. Gimple, Xiuxing Wang
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 147
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
Alexios Matikas, Dimitrios Mistriotis, Vasilios Georgoulias, et al.
Critical Reviews in Oncology/Hematology (2016) Vol. 110, pp. 1-12
Closed Access | Times Cited: 79
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy
Michael F. Emmons, Fernanda Faião‐Flores, Ritin Sharma, et al.
Cancer Research (2019) Vol. 79, Iss. 11, pp. 2947-2961
Open Access | Times Cited: 69
Postmortem proteomics to discover biomarkers for forensic PMI estimation
Kyoung‐Min Choi, Angela Zissler, Eunjung Kim, et al.
International Journal of Legal Medicine (2019) Vol. 133, Iss. 3, pp. 899-908
Open Access | Times Cited: 67
Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics
Naiara Santana-Codina, Amrita Singh Chandhoke, Qijia Yu, et al.
Cell Reports (2020) Vol. 30, Iss. 13, pp. 4584-4599.e4
Open Access | Times Cited: 66
Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma
Chuanjie Zhang, Yuxiao Zheng, Xiao Li, et al.
Annals of Translational Medicine (2019) Vol. 7, Iss. 18, pp. 427-427
Open Access | Times Cited: 62
Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 160, pp. 103234-103234
Closed Access | Times Cited: 47
Biological insights in non-small cell lung cancer
Rafael Rosell, Anisha Jain, Jordi Codony‐Servat, et al.
Cancer Biology and Medicine (2023), pp. 1-19
Open Access | Times Cited: 19
MicroRNA‐mediated drug resistance in ovarian cancer
Ainaz Mihanfar, Amir Fattahi, Hamid Reza Nejabati
Journal of Cellular Physiology (2017) Vol. 234, Iss. 4, pp. 3180-3191
Closed Access | Times Cited: 60
Therapeutics Targeting Mutant KRAS
Kyaw Zin Thein, Amadeo B. Biter, David S. Hong
Annual Review of Medicine (2020) Vol. 72, Iss. 1, pp. 349-364
Open Access | Times Cited: 49
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations
Yung-Mae Yao, Gregory P. Donoho, Philip W. Iversen, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 18, pp. 5547-5560
Open Access | Times Cited: 43
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
Marta Llauradó Fernández, Amy Dawson, Joshua Hoenisch, et al.
Cancer Cell International (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 40
MTOR inhibitor-based combination therapies for pancreatic cancer
Zonera Hassan, Christian Schneeweis, Matthias Wirth, et al.
British Journal of Cancer (2018) Vol. 118, Iss. 3, pp. 366-377
Open Access | Times Cited: 39
Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
Josef Gillson, Yogambha Ramaswamy, Gurvinder Singh, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1341-1341
Open Access | Times Cited: 38
Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
Meng Xia, Xuena Li, Yao Diao, et al.
Translational Oncology (2020) Vol. 14, Iss. 1, pp. 100920-100920
Open Access | Times Cited: 33
A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
Ting Zou, Junyan Liu, Li She, et al.
Journal of Cancer (2019) Vol. 10, Iss. 27, pp. 6848-6857
Open Access | Times Cited: 34
Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models
Aurimas Stulpinas, Matas Sereika, Aida Vitkevičienė, et al.
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 10
miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR
Huiping Ma, Weixiang Kong, Xiuying Li, et al.
Oncology Reports (2019)
Open Access | Times Cited: 29
Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression
Che-Chung Lin, I‐Ying Kuo, Liting Wu, et al.
Theranostics (2020) Vol. 10, Iss. 22, pp. 10001-10015
Open Access | Times Cited: 27
Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells
Wenxin Li, Yanwen Zhou, Xiaoqian Zhang, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 25
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I. Shapiro, Patricia LoRusso, Daniel C. Cho, et al.
Investigational New Drugs (2020) Vol. 39, Iss. 1, pp. 163-174
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top